Xofigo - Treatment for Advanced Prostate Cancer

Image credit: oncology.bayer.ie

What is Xofigo used for?

Xofigo is a brand-name prescription medication. It’s FDA-approved to treat prostate cancer that’s metastasized (spread) to your bones. Xofigo is used to treat this type of cancer when: the cancer hasn’t spread to other parts of your body, such as your liver or lungs

Can Xofigo be used off-label?

Xofigo may also be used off-label for other conditions. Off-label drug use means using a drug for a purpose other than what it’s been approved for by the FDA. Xofigo is FDA-approved to treat prostate cancer that has spread to your bones. Cancers that have spread to your bones are called bone metastases.

Can Xofigo help with prostate cancer?

This type of cancer is also called castration-resistant prostate cancer. Xofigo helps extend life for prostate cancer patients. Prostate cancer is a cancer of the prostate, a gland in the male reproductive system located below the bladder and in front of the rectum.

Is Xofigo a chemotherapy drug?

No, Xofigo isn’t a chemotherapy drug. It’s a type of drug called a radiopharmaceutical. This is a form of radiation therapy. Xofigo is absorbed into your bones like calcium. The drug gives off a small amount of radiation that kills the cancer cells in your bones. Talk with your doctor or pharmacist if you have questions about this type of therapy.

Does Xofigo kill cancer?

Xofigo contains a radioactive material called radium 233, which concentrates in the bone where there is cancer and kills the cancer cells. Xofigo treatment may help patients live longer and may slow the cancer from damaging bones, so it may be longer before you have more bone symptoms or bone fractures due to the cancer.

How long does Xofigo last?

Xofigo is given as a slow intravenous injection every 4 weeks for 6 injections. The half-life of Xofigo is 11.4 days. Xofigo treatment received FDA approval on May 15, 2013 for the treatment of patients with castration-resistant prostate cancer, who have bones symptomatic bone metastases and no known visceral metastatic disease.

What are Xofigo side effects?

Xofigo treatment received FDA approval on May 15, 2013 for the treatment of patients with castration-resistant prostate cancer, who have bones symptomatic bone metastases and no known visceral metastatic disease. The most common Xofigo side effects were nausea, diarrhea, vomiting, and peripheral edema, which affected 10% or more patients.

What Is Xofigo

1. https://www.medicalnewstoday.com/articles/drugs-xofigo
2. https://www.drugs.com/xofigo.html
3. https://www.ema.europa.eu/en/medicines/human/EPAR/xofigo
4. https://www.xofigo-us.com/patient/how-xofigo-works
5. https://www.cancerresearchuk.org/about-cancer/prostate-cancer/metastatic-cancer/treatment/radiotherapy/radium-223
6. https://www.christie.nhs.uk/media/a1ijh3s4/1073-information-about-your-radium-223-xofigo-therapy-nm.pdf
7. https://www.medicine.com/drug/xofigo
8. https://www.mskcc.org/cancer-care/patient-education/about-your-xofigo-treatment

Xofigo Information

1. https://www.hey.nhs.uk/patient-leaflet/treatment-radium-223-dichloride-xofigo-information-treatment/
2. https://oncology.bayer.ie/prostate/about-xofigor-mcrpc
3. https://www.xofigohcp.com/